CD8A and neoplasm: The therapeutic graft-versus-tumor (GVT) effect is mediated by donor-derived CD8+ T cells recognizing tumor-associated antigens (TAAs), neo-antigens or minor histocompatibility antigens (MiHAs) on recipient tumor cells [2].